ArticleACS nano2021
Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles.
Article in ACS nano, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 79 citations in OpenAlex.
- Engineering of Glioblastoma-Derived Biomimetic Vesicles and Their Structural and Molecular Features.Advanced healthcare materials · 2026Article
- Drug-free Immunotherapeutic Biomimetic Nanoparticles for Treating Triple-Negative Breast Cancer.ACS nano · 2026Article
- Selective Membrane Protein Enrichment Enables Defined Biomimetic Nanoparticles for Endothelial Targeting.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Glycyrrhizic acid-loaded biomimetic hybrid liposomes targeting inflammatory cascades and PD-1/PD-L1 pathway to reverse neuroinflammation-driven cognitive decline.Materials today. Bio · 2026Article
- Engineering Biomimetic Nanoparticle Performance Through Fabrication Method Selection: Turbulent Jet Mixing, Microfluidics, and Extrusion.Small methods · 2026Article
- A Systematic Review of Advanced Drug Delivery Systems: Engineering Strategies, Barrier Penetration, and Clinical Progress (2016-April 2025).Pharmaceutics · 2025Review
- Membrane-modified lipid nanoparticles for RNA delivery.Molecular therapy. Methods & clinical development · 2025Review
- Effect of Nanoparticle Rigidity on the Interaction of Stromal Membrane Particles with Leukemia Cells.Advanced healthcare materials · 2025Article
- Advances in research on biomaterials and stem cell/exosome-based strategies in the treatment of traumatic brain injury.Acta pharmaceutica Sinica. B · 2025Review
- Recent advances in biomimetic nanodelivery systems for cancer Immunotherapy.Materials today. Bio · 2025Review
- SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.Journal of nanobiotechnology · 2025Review
- Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Leveraging nature's nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications.Science advances · 2025Review
- Engineering Biomimetic Nanoplatforms for Acute Lung Injury: From Mechanistic Insights to Translational Opportunities.International journal of nanomedicine · 2025Review
- Optimization of Cell Membrane Purification for the Preparation and Characterization of Cell Membrane Liposomes.Small methods · 2024Article
- Unlocking the Potential of Silver Nanoparticles: From Synthesis to Versatile Bio-Applications.Pharmaceutics · 2024Review
- Cell-derived biomimetic nanoparticles for the targeted therapy of ALI/ARDS.Drug delivery and translational research · 2024Review
- Biomimetic proteolipid vesicles for reverting GPI deficiency in paroxysmal nocturnal hemoglobinuria.iScience · 2024Article
- Biomimetic Nanocarriers of Pro-Resolving Lipid Mediators for Resolution of Inflammation in Atherosclerosis.Advanced healthcare materials · 2024Article
- Exploring the Microfluidic Production of Biomimetic Hybrid Nanoparticles and Their Pharmaceutical Applications.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Biomimetic nanoparticles aim to effectively emulate the behavior of either cells or exosomes. Leukocyte-based biomimetic nanoparticles, for instance, incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.